Frontiers in Oncology (Sep 2021)
The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic
- Sudeh Izadmehr,
- Sudeh Izadmehr,
- Sudeh Izadmehr,
- Dara J. Lundon,
- Nihal Mohamed,
- Nihal Mohamed,
- Andrew Katims,
- Vaibhav Patel,
- Vaibhav Patel,
- Benjamin Eilender,
- Reza Mehrazin,
- Reza Mehrazin,
- Ketan K. Badani,
- Ketan K. Badani,
- John P. Sfakianos,
- John P. Sfakianos,
- Che-Kai Tsao,
- Che-Kai Tsao,
- Peter Wiklund,
- William K. Oh,
- William K. Oh,
- Carlos Cordon-Cardo,
- Carlos Cordon-Cardo,
- Ashutosh K. Tewari,
- Ashutosh K. Tewari,
- Matthew D. Galsky,
- Matthew D. Galsky,
- Natasha Kyprianou,
- Natasha Kyprianou,
- Natasha Kyprianou,
- Natasha Kyprianou
Affiliations
- Sudeh Izadmehr
- Department of Medicine, Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Sudeh Izadmehr
- Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Sudeh Izadmehr
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Dara J. Lundon
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Nihal Mohamed
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Nihal Mohamed
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Andrew Katims
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Vaibhav Patel
- Department of Medicine, Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Vaibhav Patel
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Benjamin Eilender
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Reza Mehrazin
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Reza Mehrazin
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Ketan K. Badani
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Ketan K. Badani
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- John P. Sfakianos
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- John P. Sfakianos
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Che-Kai Tsao
- Department of Medicine, Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Che-Kai Tsao
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Peter Wiklund
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- William K. Oh
- Department of Medicine, Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- William K. Oh
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Carlos Cordon-Cardo
- Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Carlos Cordon-Cardo
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Ashutosh K. Tewari
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Ashutosh K. Tewari
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Matthew D. Galsky
- Department of Medicine, Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Matthew D. Galsky
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Natasha Kyprianou
- Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Natasha Kyprianou
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Natasha Kyprianou
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Natasha Kyprianou
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- DOI
- https://doi.org/10.3389/fonc.2021.734963
- Journal volume & issue
-
Vol. 11
Abstract
Coronavirus disease–2019 (COVID-19), a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has become an unprecedented global health emergency, with fatal outcomes among adults of all ages throughout the world. There is a high incidence of infection and mortality among cancer patients with evidence to support that patients diagnosed with cancer and SARS-CoV-2 have an increased likelihood of a poor outcome. Clinically relevant changes imposed as a result of the pandemic, are either primary, due to changes in timing or therapeutic modality; or secondary, due to altered cooperative effects on disease progression or therapeutic outcomes. However, studies on the clinical management of patients with genitourinary cancers during the COVID-19 pandemic are limited and do little to differentiate primary or secondary impacts of COVID-19. Here, we provide a review of the epidemiology and biological consequences of SARS-CoV-2 infection in GU cancer patients as well as the impact of COVID-19 on the diagnosis and management of these patients, and the use and development of novel and innovative diagnostic tests, therapies, and technology. This article also discusses the biomedical advances to control the virus and evolving challenges in the management of prostate, bladder, kidney, testicular, and penile cancers at all stages of the patient journey during the first year of the COVID-19 pandemic.
Keywords
